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Summary
Background Globally, pneumonia is a leading cause of mortality and morbidity in children younger than 5 years. 
Underlying HIV infection is an important risk factor for pneumonia morbidity and mortality in children. There are, 
however, no global or country level estimates of pneumonia burden in HIV-infected children. We assessed the role of 
HIV in pneumonia incidence and mortality and estimated the number of pneumonia cases and deaths in HIV-
infected children younger than 5 years in 133 high pneumonia-burden countries in 2010.
Methods We estimated the risk of hospital admission and case fatality rate caused by pneumonia in HIV-infected 
children compared with HIV-uninfected children from a systematic review of studies published in Medline, Embase, 
and Global Health between Jan 1, 1980, and Aug 31, 2013. We estimated nationwide pneumonia incidence and 
mortality with two diff erent models that incorporated several risk factors for paediatric pneumonia hospital admission 
and mortality (including HIV infection). We then estimated the number of pneumonia episodes and deaths that 
occurred in HIV-infected children in 2010.
Findings The odds ratio (OR) for hospital admission for all-cause pneumonia in HIV-infected children compared 
with HIV-uninfected children was 6·5 (95% CI 5·9–7·2). The risk of death was higher in children with pneumonia 
and HIV compared with those with pneumonia only (OR 5·9, 95% CI 2·7–12·7). In 2010, 1·4 million pneumonia 
episodes (uncertainty range [UR] 0·6 million to 3·3 million) and 88 000 pneumonia deaths (UR 47 400–153 000) 
occurred in HIV-infected children in low-income countries. Of these, 1·2 million pneumonia episodes (UR 
0·5 million–2·7 million) and 85 400 deaths (UR 46 000–147 300) were directly attributable to HIV. 1·3 million 
(90%) pneumonia episodes and 82 400 (93%) pneumonia deaths in HIV-infected children aged younger than 
5 years occurred in the WHO African region.
Interpretation Globally, a small proportion of pneumonia episodes and pneumonia deaths occur in HIV-infected 
children. However, in the highest HIV-burden countries in sub-Saharan Africa (ie, Swaziland, Lesotho, and 
Zimbabwe) up to a fi fth of all pneumonia cases and 60% of pneumonia deaths occur in HIV-infected children. In 
these countries, major reductions in child pneumonia mortality can be achieved only if the systemic challenges 
plaguing the health system (poor coverage of early infant testing for HIV, of antiretroviral drugs in pregnant women 
and young children, of co-trimoxazole prophylaxis, and of pneumococcal vaccination) can be overcome.
Funding WHO.
Copyright © 2014. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.
Introduction
Estimated global deaths of children younger than 5 years 
have fallen from more than 12 million per year to fewer 
than 7 million per year in the past 20 years.1 However, 
pneumonia remains the leading cause of death of 
children outside the neonatal period, accounting for 
about 0·8 million deaths (uncertainty range [UR] 
0·68 million to 0·92 million) in 2013.2 About 120 million 
episodes (60·8 million to 277·0 million) of childhood 
pneumonia occurred worldwide in 2010, with more than 
14 million cases (10 million to 40 million) of severe 
pneumonia and 12 million hospital admissions (10 million 
to 14 million) .3,4 The high incidence of pneumonia 
globally has been strongly linked to poverty, poor living 
conditions, poor health services, malnutrition, and HIV 
infection, especially in Africa and southeast Asia, where 
the highest incidences and mortalities from pneumonia 
have been reported.
About 3·2 million children (aged 0–14 years) have HIV 
infection worldwide, with almost 90% of them in sub-
Saharan Africa.5 HIV infection is an important risk factor 
for pneumonia morbidity and mortality in children.6 
Children with HIV are at higher risk of developing severe 
or very severe pneumonia and of dying from pneumonia 
than are HIV-uninfected children.7 Additionally, HIV-
infected children not receiving antiretroviral treatment 
have poor response to empirical treatment targeted 
predominantly against Haemophilus infl uenzae type b 
and Streptococcus pneumoniae and need broad-spectrum 
antibiotics to cover a range of microbial infections.8 As 
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many as 55% of HIV-infected African children die within 
the fi rst 2 years of life in the absence of antiretroviral 
treatment,9,10 with pneumonia reported to be the main 
cause of hospital admissions and deaths in these 
children.11–13 Severe pneumonia associated with 
opportunistic infections including Pneumocystis jirovecii 
pneumonia and cytomegalovirus is common in HIV-
infected children.7
The introduction of highly active antiretroviral therapy 
in the early 2000s reduced morbidity and mortality from 
pneumonia in HIV-infected children.14 However, the 
overall incidence of pneumonia in HIV-infected children 
remains much higher than in the general population.15 
HIV-infected children still fare worse on treatment 
compared with HIV-uninfected children, suggesting the 
need for a wider range of treatments for opportunistic 
infections.16 Use of broad-spectrum antibiotics, 
pneumocystis prophylaxis, and pneumococcal conjugate 
vaccines is generally low in low-income countries, and 
coupled with the high costs of health care, has contributed 
to the high mortality from pneumonia in HIV-infected 
children.17,18 However, despite a steady global increase in 
access to antiretroviral therapy in low-income countries, 
only 34% of eligible children aged 0–14 years received 
antiretroviral therapy in 22 high priority countries in 
2012.19
At present, no estimates exist of the burden of 
pneumonia in HIV-infected children at global or country 
levels. We assessed the role of HIV in pneumonia 
incidence and mortality and estimated the number of 
pneumonia cases and deaths attributable to HIV in 
children younger than 5 years in 2010 in individual 
countries and worldwide.
Methods
Search strategy and selection criteria
We did a systematic review (according to PRISMA 
guidelines) to identify studies related to pneumonia in 
children with HIV. We searched three databases: 
Medline, Embase, and Global Health for studies 
published between Jan 1, 1980, and Aug 31, 2013 (for 
search terms, see appendix pp 3–4). We also searched 
online journals and scanned the reference lists of 
identifi ed reports.
We included studies of HIV and pneumonia providing 
numerical estimates of incidence of pneumonia and case 
fatality rates in HIV-infected or HIV-uninfected children 
aged younger than 5 years. We excluded studies without 
numerical estimates, non-human studies, studies 
without clearly defi ned study designs and diagnostic 
criteria for pneumonia and HIV, and review articles. We 
applied no language restrictions.
Procedures
We defi ned pneumonia as admission to hospital with 
cough, diffi  cult breathing, and tachypnoea either 
confi rmed by a physician or a trained care provider. We 
extracted all data onto a template in Microsoft Excel. We 
abstracted data systematically by age and various severity 
categories of all-cause pneumonia, including the number 
of cases or incidence of pneumonia, in-hospital deaths or 
case fatality rate from pneumonia, or risk estimates 
(odds ratio [OR]) and their corresponding 95% CIs for 
morbidity and mortality in HIV-infected and HIV-
uninfected children. The data were extracted by two 
independent reviewers (DOA and HN) and any 
disagreements were resolved after discussion. We also 
contacted authors for additional data when data in 
published studies were not conducive to inclusion in the 
meta-analysis.
We did a meta-analysis of risk estimates (OR) for 
disease incidence and case fatality rate for all-cause 
pneumonia in HIV-infected compared with HIV-
uninfected children (with Stata 13.1) and report pooled 
estimates and 95% CIs. We used the random eff ects 
model (DerSimonian-Laird method) to accommodate 
heterogeneity across studies included in the analysis.20
We calculated country-level estimates of clinical 
pneumonia incidence in children aged 0–4 years residing 
in 133 countries with high pneumonia mortality with an 
approach broadly similar to that used by the Child Health 
Epidemiology Reference Group (CHERG).3,21 We 
calculated the estimates from the eff ect size (risk ratio) of 
seven risk factors for clinical pneumonia (low birthweight, 
lack of exclusive breast feeding, crowding, indoor air 
pollution, malnutrition, incomplete immunisation at age 
1 year, and HIV infection) from three sources: meta-
analysis of published reports,22 prevalence of each of these 
seven risk factors at country level (from the latest 
Demographic and Health Surveys and Multiple Indicator 
Cluster Survey), and the incidence of clinical pneumonia 
in 2010 for low-income countries as a region.3 Data for 
national prevalence of all seven risk factors were available 
only for 63 countries. We imputed the missing data with 
subregional median prevalences. Children were classed 
as unexposed if they were not exposed to any of the seven 
risk factors. We assumed that incidences in unexposed 
children come from a common distribution within a 
region; that generally, rate ratios for the seven risk factors 
could be multiplied when two or more risk factors were 
present; and that risk factors were independently 
distributed within countries (appendix pp 5–9). Having 
estimated the country-specifi c incidence of clinical 
pneumonia, we calculated the incidence of pneumonia in 
HIV-infected and HIV-uninfected children, and then the 
attributable fraction for HIV with the following equation23
where Ie is the incidence of clinical pneumonia in those 
infected with HIV in each country and I0 is the incidence 
of clinical pneumonia in those uninfected with HIV in 
each country. Similarly, we estimated the total number of 
Ie – I0
Ie
Attributable fraction =
See Online for appendix
For the Demographic and 
Health Surveys see http://www.
dhsprogram.com/data/index.
cfm#CP_JUMP_13446
For the Multiple Indicator 
Cluster Survey see http://www.
childinfo.org/mics_available.
html
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deaths caused by pneumonia in 2010 for each country, 
with a single cause model (appendix pp 36–39) and did 
sensitivity analyses with the CHERG multicause 
model.24,25 We adjusted our estimates post hoc with 
national data for the use of H infl uenzae type b conjugate 
vaccine and access to antibiotics. Having obtained 
estimates of the total number of pneumonia deaths for 
each country, we calculated the number of pneumonia 
deaths in HIV-infected children, and the proportion of 
these deaths attributable to HIV (appendix pp 38–39). We 
then applied the attributable fraction to the pneumonia 
deaths in children infected with HIV (and the 95% CI) to 
obtain the number of pneumonia deaths attributable to 
HIV with an uncertainty range.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
HN had full access to all the data in the study and had the 
fi nal responsibility for the decision to submit for 
publication.
Results
We identifi ed six studies that reported odds ratio for 
clinical pneumonia morbidity (including the various sub-
categories for severity) in HIV-infected and HIV-
uninfected children (table 1, fi gure 1). Of these studies, 
only one26 was from outside sub-Saharan Africa. Four15,26–28 
were from the period before the introduction of 
antiretroviral therapy. In the two studies from after the 
introduction of antiretroviral therapy, the uptake of 
antiretroviral therapy in the study population was not 
clearly reported. Only two of the six studies included 
children in the full age range (2–59 months). Most 
investigators used modifi ed versions of the WHO 
Integrated Management of Childhood Illness case 
Study 
period
Age range Setting Design HIV case 
defi nition
Pneumonia case defi nition Category Odds ratio 
(95% CI) for 
pneumonia 
morbidity
Odds ratio for 
pneumonia 
mortality* 
(95% CI)
USA26 1990–94 0–12 months Urban Hospital-
based 
prospective 
cohort
HIV status 
confi rmed with 
PCR serum HIV 
RNA testing 
(Amplicor HIV-1 
monitor test), CDC 
classifi cation
Clinical and radiological defi nition of 
pneumonia
Clinical 
pneumonia
22·1 (6·3–77·7) ··
Nairobi, 
Kenya27
1992–98 0–24 months Mixed Prospective 
birth cohort 
study
HIV DNA PCR 
testing, WHO 
classifi cation
Clinical and radiological defi nition of 
pneumonia
Clinical 
pneumonia
1·3 (0·5–3·5) ··
Harare, 
Zimbabwe28
1997–2001 0–11 months Mixed Hospital-
based 
prospective 
cohort 
enrolled in 
trial
ELISA for samples 
collected at 
≥18 months, PCR 
for <18 months, 
WHO classifi cation
Physician diagnosed acute lower 
respiratory infection
Clinical 
pneumonia
3·0 (1·9–4·8) ··
Soweto, 
Johannesburg, 
South Africa29
1997–98 2–24 months Urban Hospital-
based 
prospective 
cohort
ELISA, based on 
CDC classifi cation
Pneumonia based on WHO criteria: 
tachypnoea (>50 breaths per min in 
children aged 2–12 months and 
>40 breaths per min in older children), 
chest wall indrawing, arterial SpO2 <90% 
on room air
Severe 
pneumonia
·· 5·6 (3·1–10·4)
Soweto, 
Johannesburg, 
South Africa15
1997–2001 2–59 months Urban Hospital-
based cohort
ELISA, HIV RNA 
PCR, CDC criteria 
for HIV
Admitted to hospital with a study 
physician diagnosis of pneumonia or 
bronchiolitis irrespective of clinical or 
radiographic features (clinical pneumonia); 
cough with lower chest wall indrawing or 
feeding diffi  culties, convulsions, central 
cyanosis, or encephalopathy, or both (very 
severe pneumonia); presence of endpoint 
consolidation (dense fl uff y opacity that 
occupies a portion or whole of the lung 
that may or may not contain air-
bronchograms) or pleural eff usion in the 
lateral pleural space that was spatially 
associated with the infi ltrate on a chest 
radiograph and confi rmed by at least two 
independent readers or one reader and 
arbiter with standard WHO training (WHO 
primary endpoint pneumonia)
Clinical 
pneumonia; 
very severe 
pneumonia; 
WHO primary 
endpoint 
pneumonia
For clinical 
pneumonia 6·5 
(5·9–7·3); for very 
severe pneumonia 
7·9 (7·1–8·9); for 
WHO primary 
endpoint 
pneumonia 14·2 
(12·8–15·9)
For clinical 
pneumonia 14·2 
(9·1–22·3)
(Table 1 continues on next page)
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defi nition for clinical pneumonia (table 1).34 All studies 
used WHO clinical staging for HIV/AIDS,35 the CDC 
classifi cation system,36 or both. They each involve a rapid 
HIV screening test and a confi rmatory HIV RNA or 
DNA PCR test to identify HIV-positive children aged 
younger than 18 months.37
The OR for hospital admission for all-cause pneumonia 
in HIV-infected children (aged 0–59 months) was 6·5 
(95% CI 5·9–7·2; appendix pp 56). In a sensitivity 
analysis including studies that had restricted age ranges, 
the OR estimates were much the same (appendix 
pp 57–58).
116·4 million episodes of pneumonia (uncertainty range 
[UR] 51·4 million to 262·6 million) occurred in 2010 in 
children younger than 5 years in the 133 high pneumonia-
burden countries (appendix pp 11–26). About a quarter 
(30·7 million) of all pneumonia episodes in low-income 
countries occurred in the WHO African region. 1·4 
million episodes of pneumonia (UR 0·6 million to 3·3 
million) occurred in HIV-infected children in low-income 
countries, of which 1·2 million episodes (UR 0·5 million 
to 2·7 million) were directly attributable to HIV. In Africa, 
1·29 million episodes of pneumonia occurred in HIV-
infected children and 1·04 million were attributable to 
Study 
period
Age range Setting Design HIV case 
defi nition
Pneumonia case defi nition Category Odds ratio 
(95% CI) for 
pneumonia 
morbidity
Odds ratio for 
pneumonia 
mortality* 
(95% CI)
(Continued from previous page)
Cape Town, 
South Africa30
1998 0–59 months Rural Hospital-
based 
prospective 
study
ELISA, HIV DNA 
PCR testing, WHO 
criteria
WHO criteria (tachypnoea or chest wall 
indrawing)
Clinical 
pneumonia
·· 2·5 (1·2–5·5)
Manhica, 
Mozambique31
2004–06 0–23 months Rural Demographic 
surveillance, 
prospective 
study
HIV infection 
defi ned according 
to WHO criteria, by 
ELISA and HIV RNA 
PCR
Physician-diagnosed pneumonia with 
chest wall indrawing (severe pneumonia); 
presence of endpoint consolidation (dense 
fl uff y opacity that occupies a portion or 
whole of the lung that may or may not 
contain air-bronchograms) or pleural 
eff usion in the lateral pleural space that was 
spatially associated with the infi ltrate on a 
chest radiograph and confi rmed by at least 
two independent readers or one reader and 
arbiter with standard WHO training (WHO 
primary endpoint pneumonia)
Severe 
pneumonia; 
WHO primary 
endpoint 
pneumonia
For severe 
pneumonia 14·9 
(10·9–20·3); for 
WHO primary 
endpoint 
pneumonia 19·7 
(12·3–31·4)
For severe 
pneumonia 12·9 
(3·7–45·4)
Kampala, 
Uganda32
2005–06 2–59 months Mixed Hospital-
based 
prospective 
cohort
HIV defi ned 
according to WHO 
criteria (DNA PCR 
for <18 months, 
rapid test for 
>18 months)
Cough or diffi  cult breathing, tachypnoea 
and chest wall indrawing
Severe 
pneumonia
·· 4·1 (1·7–10·1)
Kwazulu-
Natal and 
Limpopo 
provinces, 
South Africa33
2006–07 2–59 months Rural Hospital-
based cohort
HIV status 
confi rmed with 
PCR RNA testing, 
WHO classifi cation
Tachypnoea (>50 breaths per min in 
children aged 2–11 months, >40 breaths 
per min in older children; pneumonia); 
cough with chest indrawing with or 
without fast breathing (severe 
pneumonia)
Clinical 
pneumonia; 
severe 
pneumonia
For clinical 
pneumonia 1·8 
(1·0–3·2); for 
severe pneumonia 
7·1 (3·4–14·8)
*Ratio of case fatality rate for pneumonia in HIV-infected compared with HIV-uninfected. CDC=US Centres for Disease Control and Prevention. SpO2=peripheral capillary oxygen saturation. 
  Table 1: Characteristics of studies analysed
 Figure 1: Study selection
1780 records identified through 
searching database
2 records identified through 
other sources
177 duplicates removed
1605 screened
1483 excluded 
122 full-text articles assessed 
for eligibility
9 included in meta-analysis
113 excluded
41 did not provide estimate for children 
younger than 5 years
37 did not report pneumonia incidence, 
case-fatality rate, or risk estimates in 
HIV-positive and HIV-negative children
27 did not specify study design or clarify 
case definitions
8 provided cause-specific not all-cause risk  
estimates for pneumonia morbidity and 
mortality
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HIV (fi gure 2). 1·26 million pneumonia episodes in HIV-
infected children occurred in the 22 priority countries 
listed in UNAIDS Global Plan (table 2). The proportion of 
pneumonia episodes in HIV-infected children varies 
widely in these countries (median 6%, IQR 3–13). In 
Swaziland, Lesotho, and Zimbabwe more than 18% of all 
pneumonia episodes occurred in HIV-infected children 
and were attributable to HIV.
Five studies reported in-hospital case fatality rate for 
HIV-infected and HIV-uninfected children (table 1, 
fi gure 1). Of these studies, all but one were from southern 
sub-Saharan Africa. Studies from after the introduction 
of antiretroviral therapy31,32 did not report the uptake of 
antiretroviral therapy. Only three studies involved 
children for the full age range (2–59 months). Because 
most deaths caused by pneumonia in HIV-infected 
children occur in the fi rst year of life (with P jirovecii 
pneumonia and cytomegalovirus the most common 
causes), we also included data from studies that included 
only younger children. The ratio of case fatality rates for 
pneumonia in HIV-infected and HIV-uninfected children 
was 5·9 (95% CI 2·7–12·7; appendix pp 59–60).
Figure 2: Incidence of pneumonia attributable to HIV in children younger than 5 years in 2010, in 69 Countdown countries 
The list excludes Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, and Azerbaijan.
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According to the single cause mortality model, 921 763 
(UR 617 085–1 386 843) deaths caused by pneumonia 
occurred in young children in the post-neonatal age group 
(1–59 months) in low-income countries in 2010. Of these 
pneumonia deaths, 88 257 deaths (UR 47 387–152 268) 
occurred in HIV-infected children and 85 404 
(UR 45 853–147 344) were attributable to HIV (appendix pp 
11–24,51). These estimates are consistent with those from 
the CHERG multicause model (appendix pp 52–55).25 
82 422 pneumonia deaths (93%) in HIV-infected children 
aged younger than 5 years occurred in the WHO African 
region and 79 774 (93%) were attributable to HIV. 78 377 
deaths (88%) caused by pneumonia in HIV-infected 
children occurred in the 22 priority countries listed in 
UNAIDS Global Plan (table 2). The proportion of 
pneumonia deaths varied widely in these 22 countries 
(median 27%, IQR 14–47). In three countries—Swaziland, 
Lesotho, and Zimbabwe—more than 55% of all the 
pneumonia deaths could be attributed to HIV.
Discussion
HIV infection is an important risk factor for paediatric 
pneumonia morbidity and mortality. Our study is the 
fi rst to estimate the number of pneumonia episodes and 
deaths in HIV-infected children in low-income countries 
and provide country-level estimates for pneumonia 
morbidity and mortality attributable to HIV.
Our estimates of the number of pneumonia episodes 
and pneumonia deaths are consistent with the CHERG 
estimates (appendix pp 43–50, 61).3,25 Pneumonia 
mortality in children aged 0–4 years fell substantially 
between 2000 and 2010. After adjusting for this decrease, 
our mortality estimates are consistent with the estimates 
for pneumococcal pneumonia in HIV-infected children 
in 2000, which was estimated with an entirely diff erent 
approach and is therefore not strictly comparable.38 
Conventionally, any death of an HIV-infected child has 
had the cause of death assigned to HIV, and our analysis 
supports this approach. We have shown that, although 
only about 1% of childhood pneumonia morbidity and 
9% of mortality from childhood pneumonia are 
attributable to HIV worldwide, in the WHO African 
region, about 3% of pneumonia episodes and 17% of 
pneumonia deaths are attributable to HIV. 
These estimates have major implications for policy on 
the management of pneumonia in HIV-infected children, 
especially with respect to the revised WHO guidelines for 
antiretroviral therapy and management of community-
acquired paediatric pneumonia in HIV-infected children 
(which entails hospital admission for children with chest 
wall indrawing).35,39 Although these recommendations 
seem straightforward to implement at all levels of health 
systems, including primary care, challenges exist in 
resource-limited high-burden settings. First, after the 
implementation of antiretroviral therapy in South Africa, 
the incidence of pneumococcal pneumonia in HIV-
infected children younger than 2 years fell by 42%.40 
However, antiretroviral therapy coverage in children 
remains poor compared with adults. No global estimates 
are available for antiretroviral therapy coverage in 
children younger than 5 years. Although antiretroviral 
therapy coverage for children aged 0–14 years in the 22 priority 
countries increased in the past decade, it was still 
disappointingly low in 2011 (29%, 95% CI 26–31).19 
Coverage at the national level was highly variable, 
ranging from about 8% in Chad to more than 95% in 
Botswana. Coverage for children younger than 5 years is 
expected to be much lower and cannot be assumed to be 
the same as in older children, because the median age of 
initiating antiretroviral therapy is 4 years (Mahy M, 
UNAIDS, personal communication).
Second, although prevention of mother-to-child 
transmission of HIV coverage has increased greatly 
during the past decade, only about half of pregnant 
women with HIV in Africa received preventive treatment 
in 2010. Even if coverage was scaled up beyond 95%, a 
substantial number of new infections would still occur.41 
Third, coverage of co-trimoxazole prophylaxis for HIV in 
2011 was only 31% (95% CI 26–37), even though 
opportunistic infections are an important cause of death 
for HIV-infected children and co-trimoxazole prophylaxis 
reduces overall infection rates (not only of pneumonia, 
but also of malaria and sepsis) and has been 
recommended since 2006 as an essential part of HIV 
Proportion of all 
pneumonia 
episodes in HIV-
infected children
Proportion of all 
pneumonia 
episodes 
attributed to HIV
Proportion of all 
pneumonia deaths 
in HIV-infected 
children
Proportion of all 
pneumonia 
deaths attributed 
to HIV
Angola 2% 2% 11% 11%
Botswana 10% 8% 40% 38%
Burundi 3% 2% 13% 13%
Cameroon 4% 3% 20% 19%
Chad 4% 3% 18% 17%
Côte d’Ivoire 4% 3% 19% 18%
D R Congo 2% 1% 9% 9%
Ethiopia 3% 2% 13% 13%
Ghana 2% 1% 9% 9%
India 0% 0% 1% 1%
Kenya 6% 5% 27% 26%
Lesotho 23% 19% 64% 62%
Malawi 13% 10% 46% 45%
Mozambique 11% 9% 41% 40%
Namibia 13% 11% 48% 46%
Nigeria 4% 3% 19% 18%
South Africa 14% 12% 50% 48%
Swaziland 25% 20% 67% 64%
Uganda 7% 5% 29% 28%
Tanzania 6% 5% 27% 26%
Zambia 13% 11% 47% 45%
Zimbabwe 18% 15% 57% 55%
 Table 2: Burden of paediatric pneumonia in HIV-infected children in the 22 priority countries in the 
UNAIDS Global Plan
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care.19 Fourth, although early infant diagnosis of HIV is 
being scaled up, only about a third of infants born to 
HIV-infected mothers in 2012 were tested for HIV in the 
fi rst 2 months of life and coverage was less than 10% in 
fi ve of the priority countries (Angola, DR Congo, Malawi, 
Nigeria, and Chad).19 Implementation of a specifi c case 
management package for pneumonia in HIV-infected 
children is impossible if HIV infection status is 
unknown.39 Finally, giving pneumococcal vaccine 
(PCV-9) to HIV-infected children in South Africa reduced 
all-cause pneumonia by 13%.15 Steenhoff  and colleagues42 
have reported a 57% reduction in the incidence of 
physician-diagnosed pneumonia after introduction of 
antiretroviral therapy and PCV-7 in US children. 
Coverage of three doses of pneumococcal vaccine is 
poor, at about 19% worldwide and 21% in the WHO 
African region (ranging from 12% in Ethiopia to 99% in 
Malawi) in 2012.43 Moreover, seven of the 22 priority 
countries are yet to introduce the vaccine.44
Several factors aff ect our estimates. Although the case 
defi nitions used by the various studies in our meta-
analysis were broadly similar, they varied substantially in 
their specifi c eligibility criteria. Similarly, although we 
only included studies that used a rapid test for HIV 
screening followed by confi rmation by PCR, there is 
probably some variation in the sensitivity and specifi city 
of the study-specifi c test kits. We believe that these 
diff erences, along with the precise study designs, would 
have contributed to heterogeneity in the estimates. In 
most cases, HIV status was tested only after hospital 
admission, and is unlikely to have biased the results. The 
included studies report wide variations in case fatality 
rate for the two groups—about a fi ve-times diff erence in 
HIV-uninfected children and two-times diff erence in 
HIV-infected children. This diff erence could be a result 
of access to care (in the former), and quality of care and 
range of pathogens (in the latter). Our systematic review 
returned only nine studies, most from southern Africa. 
However, all were of high quality and fulfi lled our strict 
eligibility criteria and reported data for HIV-negative and 
HIV-positive children. The results of the individual 
studies that contributed to the analysis are consistent 
(appendix pp 56–58). The geographical clustering is not 
surprising given that 21 of the 22 high priority countries 
are in sub-Saharan Africa and of these, nine (some with 
the highest burden) are in southern Africa (UNAIDS 
data13).
Antiretroviral therapy coverage was not reported in the 
studies, nor was its eff ect on the risk of all-cause 
pneumonia in HIV-infected children. Therefore, we 
could not adjust the estimates for access to antiretroviral 
therapy, especially in the fi rst few months of life, when it 
has a major eff ect on morbidity and mortality.45 This 
shortcoming could have resulted in some overestimation 
of the incidence of pneumonia in HIV-infected children. 
This uncertainty is compounded by the case 
ascertainment used in the studies to calculate the odds 
ratio for pneumonia morbidity and mortality in HIV-
infected compared with HIV-uninfected children. All the 
studies were hospital-based, and therefore, these 
estimates would be aff ected by health-care seeking 
behaviour, which is typically poor in low-income 
countries, resulting in underestimation of the burden. 
More importantly, we might have underestimated the 
role of HIV infection in paediatric pneumonia by only 
considering HIV-infected children in the exposed group. 
However, HIV exposed but uninfected children (ie, HIV-
negative children born to HIV-positive mothers) are at a 
much higher risk of developing severe pneumonia, 
treatment failure, and death compared with unexposed 
children.46 Additionally, our estimates are probably 
conservative because very young infants are not routinely 
tested for HIV, even in the priority countries.
The national estimates for pneumonia morbidity and 
mortality and the proportion of pneumonia cases and 
deaths attributable to HIV depend on the quality of local 
data for prevalence of risk factors included in the model. 
Such data were missing for at least one risk factor in 70 
of the 133 countries. Although we imputed the missing 
data, our sensitivity analyses suggested that our estimates 
are not sensitive to imputation (appendix pp 27–35). 
Although our estimates of HIV prevalence in children 
younger than 5 years take into consideration coverage 
and effi  cacy of preventing mother-to-child transmission, 
prevalence of breastfeeding, and transmission of HIV in 
breast milk, data were either poor or missing for some 
countries (especially outside Africa). For the morbidity 
model, we assumed that all seven risk factors included in 
the model were distributed independently within 
countries. This assumption is unlikely to be true because 
these factors are linked to socioeconomic characteristics 
such as deprivation. There is likely to be some (unknown) 
degree of correlation between these risk factors. Similarly, 
we assumed that the risk ratios for each risk factor were 
the same across the low-income countries and that the 
risk ratios combined multiplicatively (with a weak 
interaction term). Our mortality estimates are restricted 
to children aged 1–59 months because much of the eff ect 
of paediatric HIV on mortality occurs after the neonatal 
period. Further studies are needed to understand how 
risk factors cluster in populations, to estimate cause-
specifi c pneumonia burden in HIV-infected children, 
and to identify appropriate antibiotic treatment regimens 
for pneumonia in HIV-infected children.
Our estimates have important policy implications. 
Management of pneumonia in HIV-infected children 
needs a multipronged integrated approach both from 
national governments and international agencies. Case 
ascertainment (of both pneumonia and HIV by PCR 
virological testing) needs to be strengthened in primary 
care, and antiretroviral therapy in pregnant women and 
young children need to be rapidly scaled up, along with 
co-trimoxazole prophylaxis coverage. Priority countries 
that have not yet introduced pneumococcal conjugate 
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vaccine should consider doing so, at least for HIV-
infected children. Simultaneously, the revised WHO 
guidelines for management of childhood pneumonia39,47 
should be implemented fully if further substantial falls 
in pneumonia morbidity and mortality are to be achieved 
in high HIV burden countries.
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